Zambon Company S.p.A.

Company Profile

Publication Date: 4 Jan 2012
ABOUT DATAMONITOR

Datamonitor is a leading business information company specializing in industry analysis.


The company also advises clients on the impact that new technology and eCommerce will have on their businesses. Datamonitor maintains its headquarters in London, and regional offices in New York, Frankfurt, and Hong Kong. The company serves the world's largest 5000 companies.

Datamonitor’s premium reports are based on primary research with industry panels and consumers. We gather information on market segmentation, market growth and pricing, competitors and products. Our experts then interpret this data to produce detailed forecasts and actionable recommendations, helping you create new business opportunities and ideas.

Our series of company, industry and country profiles complements our premium products, providing top-level information on 10,000 companies, 2,500 industries and 50 countries. While they do not contain the highly detailed breakdowns found in premium reports, profiles give you the most important qualitative and quantitative summary information you need - including predictions and forecasts.

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Datamonitor plc.

The facts of this profile are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.
TABLE OF CONTENTS

Company Overview........................................................................................................4
Key Facts..................................................................................................................4
Business Description..............................................................................................5
History....................................................................................................................6
Key Employees.......................................................................................................8
Major Products and Services..................................................................................9
Top Competitors...................................................................................................11
Locations and Subsidiaries.....................................................................................12
COMPANY OVERVIEW

Zambon Company (Zambon) is a biotechnology company specialized in manufacturing pharmaceuticals and fine chemicals. The company, through its subsidiaries produces pharmaceuticals for respiratory, pain management and women healthcare; and fine chemicals such as custom synthesis and generics active pharma ingredients (APIs). The company primarily operates in Europe, South America and Asia. It is headquartered in Bresso, Italy and employs around 2,415 people.

The company recorded revenues of E545 million (approximately $723.7 million) in the fiscal year ended December 2010, an increase of 0.6% over 2009.

KEY FACTS

<table>
<thead>
<tr>
<th>Head Office</th>
<th>Zambon Company S.p.A. Via Lillo Del Duca 10 10-20091 Bresso ITA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone</td>
<td>39 02 665241</td>
</tr>
<tr>
<td>Fax</td>
<td>39 02 66501492</td>
</tr>
<tr>
<td>Web Address</td>
<td><a href="http://www.zambongroup.com">http://www.zambongroup.com</a></td>
</tr>
<tr>
<td>Revenue / turnover</td>
<td>545.0</td>
</tr>
<tr>
<td>(EUR Mn)</td>
<td></td>
</tr>
<tr>
<td>Financial Year End</td>
<td>December</td>
</tr>
<tr>
<td>Employees</td>
<td>2,415</td>
</tr>
</tbody>
</table>
BUSINESS DESCRIPTION

Zambon Company (Zambon), through its subsidiaries is engaged in manufacturing pharmaceuticals and fine chemicals. The company primarily operates in Europe, South America and Asia with production plants located in Italy, Switzerland, France and China.

The company operates through two segments: pharmaceuticals and fine chemicals.

Zambon's pharmaceuticals segment is operated through its subsidiary, Zambon Pharma. The company produces pharmaceuticals in three areas respiratory, pain management and women healthcare. It offers therapeutic solutions for treatment of main pathologies with products made of N-acetylcysteine or cloperastine. Zambon Pharma develops a range of medical devices studied for childrens' and adults' breath wellness. Fluirespira offers a range of products, mainly tailored to support cure, to sustain prevention, daily hygiene and for children' and all family breath protection.

Zambon Pharma develops the combination of ibuprofen and arginine for pain management. The company also offers a drug, analgesics, which is used in nervous transmission, blocking the connection between the epithelium and the brain. It develops an antibiotic made of fosfomycin trometamol, which is generally administered as one shot therapy for urinary infections. The company also produces a natural product, Monurelle, made of cranberry and vitamin C for Cystitis.

The company's fine chemicals segment comprises of ZaCh System, a subsidiary that manufactures fine chemicals. ZaCh System operates two manufacturing plants: Lonigo plant in Italy and Avrille plant in France. The company offers two products: custom synthesis and generics active pharma ingredients (APIs). Custom synthesis include chiral and asymmetric synthesis, metal hydride reduction, catalytic hydrogenation, aminoacids protection and derivatization, cryogenic carbonionic chemistry, cyanation, hofmann rearrangement and hofmann elimination, ozonolysis, organometallic chemistry, ion exchange chromatography, phosgene (g) free phosgenation, sulfur chemistry, heterocyclic chemistry, azide chemistry, epoxide synthesis and enzymatic chemistry.

ZaCh System's generic active pharmaceutical ingredients (APIs) include gabapentin, N-Acetyl-L-Cysteine, carvedilol, sulindac, carvedilol phosphate, diltiazem hydrochloride, nifedipine, levetiracetam, propofol, thiamphenicol, dorzolamide hydrochloride, trimebutine maleate, clopidogrel, nebulol hydrochloride and olopatadine hydrochloride. The company's API's under development include Abiraterone Acetate for prostate cancer treatment; Alcaftadine, an anti-allergic ophthalmic agent; Cinacalcet for hyperparathyroidism; and Retigabine, an antipiletic drug for neuropathic pain.
HISTORY

Zambon Company (Zambon) was founded in 1906 in Vicenza, Italy as Magazzino medicinali Zambon together with Silvio Farina, for trading chemical products.

The company was named to Gaetano Zambon e c. in 1908.

In 1920, Gaetano Zambon began producing galenical preparations. In 1928, the company and Silvio Farina formed an industrial organisation under the trade name ZEF.

The company began synthesis of raw materials during 1932 to 1933. In 1938, the first Zambon research laboratory was opened in Vicenza.

In 1946, the company established Zambon plant in Vicenza, Italy. In 1956, the first branch of Zambon was opened in Brazil.

Zambon collaborated with Parke Davis in 1958.

During 1965-1975, the company expanded its operations in European countries, and Central and South America.

The company identified a new molecule (Fosfomycin Trometamol) in 1979. In 1983, Zambon acquired Milanese pharmaceutical firm SIMES.

In 1995, the Zambon Company expanded its operations in the East, and opened branches in Russia and Hong Kong and launched the first joint venture in China. In the same year, the company got approval from the US FDA for the production of fosfomycin trometamol for the US market.

The company made agreements with various international pharmaceutical companies for the marketing of molecules resulting from Zambon research, and for the production of raw materials and generic drugs in 2000. In the same year, Zambon established Chinese plant.

In 2002, the company acquired Laboratoires Laphal, the French pharmaceutical company. In the same year, Zambon opened its new branch in India.

The company formed a subsidiary Z-Cube to identify and support the validation of drug delivery technologies, in 2003.

In 2007, Zambon signed a distribution agreement with Pierre Fabre Medicament to produce several products including the antibiotic Monuril, the mucolytic Flumicil, the antibiotic Lorafem and the anti-infective Panotile Cipro. In the same year, the company acquired PPG Fine Chemicals, to expand the chemical division of Zambon.
The company’s subsidiary, Z-Cube Srl and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, entered into a license agreement, to develop and commercialize a nanotechnology drug delivery system for the treatment of pain, in 2009. In the same year, Zambon Spa and Indena Spa, a company engaged in the research and production of plant-derived pharmaceutical active ingredients entered into a licensing and cooperation agreement for a new semi-synthetic molecule in pain therapeutic area.

In 2010, Zcube, a subsidiary of the company and Arizona Technology Enterprises (AzTE) entered into a licensing agreement, enabling Zcube to use ASU technology to develop and commercialize medical devices and to monitor and treat chronic respiratory diseases like asthma.

In March 2011, ZCube and UCSF (University of California San Francisco) signed an agreement, enabling ZCube use microtechnology developed by the UCSF to administer oral medications.
## KEY EMPLOYEES

<table>
<thead>
<tr>
<th>Name</th>
<th>Job Title</th>
<th>Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margherita Zambon</td>
<td>Chairman</td>
<td>Non Executive Board</td>
</tr>
</tbody>
</table>
MAJOR PRODUCTS AND SERVICES

Zambon Company (Zambon) is an Italy-based biotechnology company that specializes in producing pharmaceuticals and fine chemicals. The company’s key products include the following:

Products:

Pharmaceuticals:

Products for respiratory problems
Pain management products
Women healthcare products

Fluimicil
Monuril
Spidifen
Espidifen
Monural
Monurol
Spidufen
Spididol
Spedifen
Espididol
Faspic
Rinofluimucil
Seki
Anauran
Panotile
Ursacol
Ursochol

Fine chemicals:

Custom synthesis:

Chiral and asymmetric synthesis
Metal hydride reduction
Catalytic hydrogenation
Aminoacids protection and derivatization
Cryogenic carbanionic chemistry
Cyanation
Hofmann rearrangement and hofmann elimination
Ozonolysis
Organometallic chemistry
Ion exchange chromatography  
Phosgene (g) free phosgenation  
Sulfur chemistry  
Heterocyclic chemistry  
Azide chemistry  
Epoxide synthesis  
Enzymatic chemistry  

Generic active pharmaceutical ingredients (APIs):  

Gabapentin  
N-Acetyl-L-Cysteine  
Carvedilol  
Sulindac  
Carvedilol phosphate  
Diltiazem hydrochloride  
Nifedipine  
Levetiracetam  
Propofol  
Thiamphenicol  
Dorzolamide hydrochloride  
Trimebutine maleate  
Clopidogrel  
Nebivolol hydrochloride  
Olopatadine hydrochloride  

Products pipeline (APIs):  

Abiraterone Acetate (for prostate cancer treatment)  
Alcaftadine (anti-allergic ophthalmic agent)  
Cinacalcet (for hyperparathyroidism)  
Retigabine (antipiletic drug for neuropathic pain)
TOP COMPETITORS

The following companies are the major competitors of Zambon Company S.p.A.

Recordati S.p.A.
Chiesi Farmaceutici S.p.A.
sigma-tau s.p.a.
Cambrex Profarmaco
## LOCATIONS AND SUBSIDIARIES

### Head Office
Zambon Company S.p.A.  
Via Lillo Del Duca 10  
10-20091 Bresso  
ITA  
P:39 02 665241  
F:39 02 66501492  
http://www.zambongroup.com

### Other Locations and Subsidiaries

<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zambon S.p.A.</td>
<td>Via Lillo del Duca 10</td>
<td>Milan</td>
<td>ITA</td>
</tr>
<tr>
<td>Zach System S.p.A.</td>
<td>Via Lillo del Duca 10 20091 Bresso</td>
<td>Milan</td>
<td>ITA</td>
</tr>
<tr>
<td>Zcube S.r.l.</td>
<td>Via Lillo del Duca 10 20091 Bresso</td>
<td>Milan</td>
<td>ITA</td>
</tr>
<tr>
<td>Zambon Italia Srl</td>
<td>Via Lillo del Duca 10 20091 Bresso</td>
<td>Milan</td>
<td>ITA</td>
</tr>
<tr>
<td>Zambon Switzerland Ltd.</td>
<td>Via Industria 13 6814 Cadempino</td>
<td>Milan</td>
<td>CHE</td>
</tr>
<tr>
<td>Zambon France S.A.</td>
<td>13 Rue Rene Jacques 92138 Issy Les Moulineaux Cedex</td>
<td>92138 Issy Les Moulineaux Cedex</td>
<td>FRA</td>
</tr>
<tr>
<td>Zambon S.A./N.V.</td>
<td>Avenue E Demunterlaan 1/9 1090 Bruxelles</td>
<td>Brussels</td>
<td>BEL</td>
</tr>
<tr>
<td>Zambon Nederland B.V.</td>
<td>Basicweg 14b 3821 BR Amersfoort</td>
<td>Amersfoort</td>
<td>NLD</td>
</tr>
<tr>
<td>Zambon Laboratorios Farmaceuticos Ltda.</td>
<td>Avenida Ibirapuera 2332-12 piano Torre 1 Moema San Paolo</td>
<td>San Paolo</td>
<td>BRA</td>
</tr>
<tr>
<td>Zambon Pharma Ltd.</td>
<td>Glazovsky per Building 7 Office 17 119002 Mosca</td>
<td>Mosca</td>
<td>RUS</td>
</tr>
</tbody>
</table>
| P.T. Zambon Indonesia  
Graha Fatmawati Jalan R.S. Fatmawati  
Raja Blok A N.1C  
Jakarta Selatan  
IDN | Hainan Zambon Pharmaceutical Co., Ltd.  
Haikou National  
Hi-tech Industrial Development Zone  
Haikou  
Hainan 570314  
CHN |
|---|---|
| Zambon (India) Pvt. Ltd.  
Main Mehrauli Gurgaon Road  
Suite No. 301 3rd Floor  
JMD - Regent Square  
Gurgaon 122001  
Haryana  
IND | Zambon Company (Chemical Plant)  
Via Dovaro  
36045 Almisano di Lonigo  
Vicenza  
ITA |